RTOG-0913

Trial

Clinical Trial Title

RTOG-0913

Trial Status

Open to Enrollment

Start Date

February 1, 2013

Location

Trial Type

Cancer (Oncology)

Specific Condition

Newly Diagnosed Glioblastoma

Description

A Phase I/II Trial of Concurrent RAD001 (Everolimus) With Temozolomide/Radiation Followed by Adjuvant RAD001/Temozolomide in Newly Diagnosed Glioblastoma

Eligibility Criteria

  •  Patient must have histopathologically confirmed glioblastoma or gliosarcoma(WHO Grade IV) confirmed by central pathology tissue screening
  • Patient  must have recovered from the effects of surgery, postoperative infection, and other complications
  • Is the patient’s age ≥ 18?

IRB Number

Legacy IRB

Notes

Sponsored by: the Radiation Therapy Oncology Group

Principal Investigator Name

Andrew Kee, MD

Contact Name

Legacy Oncology Clinical Research

Phone

503-413-8199

Contact Fax

503-413-6920

Last Updated: Wednesday, September 18, 2013 01:56:55 PM